Contrasting PTH Response of Denosumab Use in Dialysis Patients: A Report of 2 Cases.

A common complication of end-stage renal disease (ESRD) is mineral and bone disorder. Yet, many anti-osteoporotic drugs are contraindicated in ESRD patients. Denosumab, a monoclonal antibody, does not require renal dose adjustment.